22/12/2025 08:55
|
Biotechnology
Key Facts: · Superior Tumour Inhibition – INOVIQ’s CAR-NK-EV therapeutic candidate achieved 61.5% tumour reduction over 28 days, outperforming unmodified NK-EVs
· 100% Survival –...